7Baggers

Ironwood Pharmaceuticals, Inc
(NASDAQ:IRWD) 

IRWD stock logo

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chroni...

Founded: 1998
Full Time Employees: 317
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-09-30 2015-06-30 2015-03-31 2014-09-30 2014-06-30 2014-03-31 2013-09-30 2013-06-30 2013-03-31 2012-09-30 2012-06-30 2012-03-31 2011-09-30 2011-06-30 2011-03-31 2010-09-30 2010-06-30 2010-03-31 
                                                               
      revenues:
    		                                                           
      collaborative arrangements revenue
    		106,506,000 47,709,000 122,060,000 85,239,000 41,143,000 90,545,000 91,592,000 94,396,000 74,877,000 117,553,000 113,739,000 107,382,000 104,061,000 107,199,000 108,637,000 97,231,000 97,529,000 116,986,000 103,747,000 103,386,000 88,665,000 114,209,000 103,468,000 89,423,000 74,445,000 105,654,000 130,524,000 77,322,000 66,152,000 84,352,000 54,194,000 71,207,000 63,086,000 62,901,000 86,143,000 64,612,000 51,877,000 87,459,000 66,106,000 54,350,000 66,042,000 39,572,000 27,744,000 28,932,000 16,918,000 6,840,000 14,605,000 4,932,000 9,663,000 3,255,000 96,413,000 14,604,000 12,248,000 12,218,000 11,262,000 10,237,000 9,059,000   
      total revenues
    		106,506,000 47,709,000 122,060,000 85,239,000 41,143,000 90,545,000 91,592,000 94,396,000 74,877,000 117,553,000 113,739,000 107,382,000 104,061,000 107,199,000 108,637,000 97,231,000 97,529,000 117,130,000 103,747,000 104,031,000 88,845,000 116,680,000 103,468,000 89,432,000 79,943,000 126,301,000 131,167,000 102,215,000 68,730,000 130,692,000 65,686,000 81,106,000 69,155,000 94,208,000 86,825,000 65,077,000 52,166,000                       
      yoy
    		158.87% -47.31% 33.26% -9.70% -45.05% -22.98% -19.47% -12.09% -28.05% 9.66% 4.70% 10.44% 6.70% -8.48% 4.71% -6.54% 9.77% 0.39% 0.27% 16.32% 11.14% -7.62% -21.12% -12.51% 16.31% -3.36% 99.69% 26.03% -0.61% 38.73% -24.35% 24.63% 32.57%                           
      qoq
    		123.24% -60.91% 43.20% 107.18% -54.56% -1.14% -2.97% 26.07% -36.30% 3.35% 5.92% 3.19% -2.93% -1.32% 11.73% -0.31% -16.73% 12.90% -0.27% 17.09% -23.86% 12.77% 15.69% 11.87% -36.70% -3.71% 28.32% 48.72% -47.41% 98.96% -19.01% 17.28% -26.59% 8.50% 33.42% 24.75%                        
      costs and expenses:
    		                                                           
      research and development
    		21,940,000 21,863,000 22,468,000 23,373,000 27,432,000 25,391,000 29,827,000 30,388,000 25,815,000 35,676,000 32,985,000 34,577,000 12,847,000 10,446,000 11,545,000 11,452,000 10,822,000 31,851,000 10,907,000 12,163,000 15,484,000 16,267,000 21,692,000 22,076,000 28,027,000 26,537,000 27,551,000 28,758,000 53,990,000 44,272,000 46,794,000 38,932,000 36,505,000 40,117,000 37,065,000 37,344,000 33,702,000 38,442,000 37,526,000 31,682,000 31,842,000 25,830,000 28,648,000 26,641,000 25,122,000 22,142,000 27,144,000 23,016,000 24,093,000 32,753,000 23,453,000 32,238,000 29,510,000 22,905,000 19,409,000 19,555,000 18,742,000 20,953,000 18,637,000 
      selling, general and administrative
    		12,033,000 19,293,000 21,908,000 16,795,000 24,260,000 33,590,000 36,113,000 36,964,000 37,605,000 38,667,000 36,046,000 52,484,000 31,117,000 28,390,000 28,619,000 30,124,000 28,861,000 28,687,000 27,742,000 27,052,000 27,652,000 33,982,000 34,928,000 34,643,000 36,450,000 39,190,000 40,919,000 43,246,000 64,741,000 58,179,000 55,248,000 68,363,000 61,923,000 57,953,000 61,774,000 57,792,000 55,604,000 55,208,000 44,987,000 36,918,000 36,168,000 30,439,000 32,955,000 30,346,000 28,535,000 29,299,000 29,924,000 30,264,000 30,870,000 33,374,000          
      restructuring
    		-40,000 -252,000 2,200,000 -250,000 18,559,000 73,000 16,000 2,067,000                                                    
      total costs and expenses
    		33,933,000 40,904,000 46,576,000 39,918,000 70,251,000 59,054,000 65,956,000 69,419,000 63,857,000 79,964,000 73,716,000 1,190,521,000                                                
      income from operations
    		72,573,000 6,805,000 75,484,000 45,321,000 -29,108,000 31,491,000 25,636,000 24,977,000 11,020,000 37,589,000 40,023,000 -1,083,139,000 60,097,000 68,363,000 68,473,000 55,655,000 57,846,000 56,592,000 65,171,000 65,098,000 45,398,000 51,384,000 45,616,000 32,713,000 13,227,000 49,593,000 65,887,000 21,577,000 -54,372,000 5,995,000 -169,099,000 -39,920,000 -35,868,000 22,765,000 -19,434,000 -41,011,000 -39,705,000 -6,300,000 -28,287,000            47,608,000         
      yoy
    		-349.32% -78.39% 194.45% 81.45% -364.14% -16.22% -35.95% -102.31% -81.66% -45.02% -41.55% -2046.17% 3.89% 20.80% 5.07% -14.51% 27.42% 10.14% 42.87% 99.00% 243.22% 3.61% -30.77% 51.61% -124.33% 727.24% -138.96% -154.05% 51.59% -73.67% 770.12% -2.66% -9.66% -461.35% -31.30%                         
      qoq
    		966.47% -90.98% 66.55% -255.70% -192.43% 22.84% 2.64% 126.65% -70.68% -6.08% -103.70% -1902.32% -12.09% -0.16% 23.03% -3.79% 2.22% -13.16% 0.11% 43.39% -11.65% 12.64% 39.44% 147.32% -73.33% -24.73% 205.36% -139.68% -1006.96% -103.55% 323.59% 11.30% -257.56% -217.14% -52.61% 3.29% 530.24% -77.73%                      
      operating margin %
    		68.14% 14.26% 61.84% 53.17% -70.75% 34.78% 27.99% 26.46% 14.72% 31.98% 35.19% -1008.68% 57.75% 63.77% 63.03% 57.24% 59.31% 48.32% 62.82% 62.58% 51.10% 44.04% 44.09% 36.58% 16.55% 39.27% 50.23% 21.11% -79.11% 4.59% -257.44% -49.22% -51.87% 24.16% -22.38% -63.02% -76.11% -Infinity% -Infinity% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% Infinity% NaN% NaN% NaN% NaN% NaN% NaN% NaN% NaN% 
      other income:
    		                                                           
      interest expense and other financing costs
    		-9,141,000 -7,886,000 -8,434,000 -8,356,000 -8,070,000 -8,914,000 -9,419,000 -7,470,000 -7,231,000 -8,423,000 -9,839,000 -1,840,000                                                
      interest and investment income
    		1,698,000 1,459,000 930,000 818,000 869,000 778,000 1,152,000 1,369,000 1,169,000 1,194,000 1,748,000 8,757,000 7,272,000 5,446,000 2,807,000 1,018,000 230,000 180,000 178,000 172,000 196,000 220,000 231,000 276,000 777,000 565,000 893,000 668,000 736,000 837,000 741,000 732,000 681,000 619,000 601,000 496,000 395,000 346,000 307,000 295,000 221,000 156,000 71,000 65,000 71,000 65,000 44,000 41,000 49,000 52,000 41,000 44,000 49,000 105,000 125,000 154,000 188,000 189,000 68,000 
      other
    		42,000 77,000 40,000 39,000 37,000                                                       
      other income
    		-7,401,000 -6,350,000 -7,464,000 -7,499,000 -7,164,000 -7,496,000 -8,267,000 -6,101,000 -6,062,000 -7,229,000 -8,091,000 6,917,000 5,764,000         -3,000   27,000 306,000 68,000 140,000                          897,000  3,000 107,000 110,000  
      income before income taxes
    		65,172,000 455,000 68,020,000 37,822,000 -36,272,000 23,995,000 17,369,000 18,876,000 4,958,000 30,360,000 31,932,000 -1,076,222,000 65,861,000 72,265,000 69,907,000 53,785,000 56,465,000 38,600,500 59,672,000 54,372,000 40,358,000                                       
      income tax expense
    		-24,399,000 -2,731,000 -27,940,000 -14,223,000 -1,114,000 -21,739,000 -13,723,000 -19,736,000 -9,120,000 -12,846,250 -17,982,000 -13,256,000 -20,147,000    -17,664,000    -432,000 1,296,000 1,389,000                               3,000      
      net income
    		40,773,000 -2,276,000 40,080,000 23,599,000 -37,386,000 2,256,000 3,646,000 -860,000 -4,162,000 -1,745,000 13,950,000               47,858,000 20,648,000 12,283,000 -59,284,000 -15,493,000 -174,351,000 -49,380,000 -43,144,000 12,085,000 -32,297,000 -44,224,000 -52,501,000 -13,505,000 -33,204,000 -21,702,000 -13,297,000 -47,390,000 -48,020,000 -33,222,000 -41,988,000 -60,357,000 -49,626,000 -61,775,000 -65,149,000 -93,902,000 47,635,000 -40,803,000        
      yoy
    		-209.06% -200.89% 999.29% -2844.07% 798.27% -229.28% -73.86%                   -408.90% -111.84% -124.87% 37.41% -228.20% 439.84% 11.66% -17.82% -189.49% -2.73% 103.78% 294.83% -71.50% -30.85% -34.68% -68.33% -21.48% -3.24% -46.22% -35.55% -35.72% -204.18% 51.40%            
      qoq
    		-1891.43% -105.68% 69.84% -163.12% -1757.18% -38.12% -523.95% -79.34% 138.51% -112.51%                131.78% 68.10% -120.72% 282.65% -91.11% 253.08% 14.45% -457.00% -137.42% -26.97% -15.77% 288.75% -59.33% 53.00% 63.21% -71.94% -1.31% 44.54% -20.88% -30.43% 21.62% -19.67% -5.18% -30.62% -297.13% -216.74%         
      net income margin %
    		38.28% -4.77% 32.84% 27.69% -90.87% 2.49% 3.98% -0.91% -5.56% -1.48% 12.26% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 37.89% 15.74% 12.02% -86.26% -11.85% -265.43% -60.88% -62.39% 12.83% -37.20% -67.96% -100.64% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% Infinity% -Infinity% NaN% NaN% NaN% NaN% NaN% NaN% NaN% 
      net income per share
    		0.25 -0.01 0.25 0.15 -0.23 0.02 0.02 -0.01 -0.03  0.1 -6.84 0.3 0.31 0.33 0.24 0.25 0.25 0.34 2.42 0.25 0.27 0.22 0.16 0.02 0.31 0.13 0.08 -0.38 -0.1 -1.14 -0.32 -0.29 0.09 -0.22 -0.3 -0.36 -0.09 -0.23 -0.15 -0.09 -0.33 -0.34 -0.24 -0.3 -0.44 -0.38  -0.57 -0.87  -0.38 -0.34 -0.21 -0.19 -0.19 -0.08 -0.18 -0.25 
      weighted-average shares used for eps calculation
    		163,451 161,842 162,215 161,723 160,974 159,083 159,706 159,014 157,700 155,435 155,886 155,367 154,452 154,366 153,066 153,304 157,821 162,245 162,742 161,948 160,967 159,427 159,846 159,407 158,374                                   
      acquired in-process research and development
    		         5,000,000  1,090,449,000                                                
      gain on derivatives
    		            19,000 -18,000 151,000 -681,000 730,000 -2,566,000 2,164,000  2,390,000   -467,000 -3,466,000 4,517,000 -4,766,000 -672,000 3,944,000 -12,739,000 3,489,000 -809,000 1,316,000 -2,093,000 -4,329,000 5,337,000  2,103,000 4,541,000 3,145,000                    
      less: net loss attributable to noncontrolling interests
    		                                                           
      net income attributable to ironwood pharmaceuticals, inc.
    		     2,256,000 3,646,000   -1,087,000 15,321,000                                                 
      net loss attributable to ironwood pharmaceuticals, inc.
    		       -860,000                                              -20,633,000 -18,844,000 -18,401,000 -8,270,000 -17,136,000 -15,924,000 
      restructuring expenses
    		        437,000 621,000 4,685,000 13,011,000       -73,000 -282,000 311,000 14,150,000 1,232,000   -32,000 -166,000 490,000 3,328,000 783,000 10,282,000 2,392,000                            
      less: net income attributable to noncontrolling interests
    		         -658,000 -1,371,000                                                 
      net income and comprehensive income
    		           -1,089,478,000 45,714,000 48,867,000 50,317,000 37,080,000 38,801,000 41,374,000 55,845,000 391,303,000 39,926,000 15,743,000 34,423,000 25,204,000 3,345,000                                   
      less: net income and comprehensive income attributable to noncontrolling interests
    		           -27,291,000                                                
      net income and comprehensive income attributable to ironwood pharmaceuticals, inc.
    		           -1,062,187,000                                                
      operating expenses:
    		                                                           
      total operating expenses
    		            43,964,000 38,836,000 40,164,000 41,576,000 39,683,000                                  48,805,000 55,438,000 47,884,000 33,834,000 30,214,000 28,779,000 25,224,000 28,278,000 25,280,000 
      interest expense
    		            -1,527,000 -1,526,000 -1,524,000 -2,207,000 -2,341,000 -7,951,000 -7,841,000 -7,732,000 -7,626,000 -7,521,000 -7,419,000 -7,318,000 -7,220,000 -7,123,000 -10,457,000 -9,430,000 -9,592,000 -9,586,000 -9,482,000 -9,383,000 -9,273,000 -9,206,000 -9,135,000 -9,046,000 -8,983,000 -9,654,000 -9,765,000                     
      sale of active pharmaceutical ingredient
    		                 144,000  645,000 180,000 2,471,000  9,000 5,498,000 20,647,000 643,000 24,893,000 2,578,000 45,861,000 10,257,000 8,803,000 5,434,000                           
      other expense
    		             -454,250 1,434,000 -1,870,000 -1,381,000 -10,337,000 -5,499,000 -10,726,000 -5,040,000 -6,884,000 -9,804,000 -7,509,000 -9,882,000 -1,735,000 -45,239,000 -9,294,000 -4,912,000 -21,488,000 -5,252,000 -9,460,000 -7,276,000 -10,680,000 -12,863,000 -3,213,000 -12,796,000 -7,205,000 -4,917,000                     
      income tax benefit
    		             -23,398,000 -19,590,000 -16,705,000  -4,881,000 -3,827,000 336,931,000                                        
      cost and expenses:
    		                                                           
      cost of revenues
    		                     559,750   2,239,000                                   
      total cost and expenses
    		                 60,538,000 38,576,000 38,933,000 43,447,000 65,296,000 57,852,000 56,719,000 66,716,000 76,708,000 65,280,000 80,638,000 123,102,000 124,697,000 234,785,000 121,026,000 105,023,000 71,443,000 106,259,000 106,088,000 91,871,000 93,759,000 94,393,000 69,665,000 68,010,000 65,757,000 69,753,000 56,999,000 53,657,000 61,959,000 58,992,000 61,483,000 69,543,000 92,088,000          
      loss on derivatives
    		                   -3,166,000  -1,637,250 -2,616,000              -2,199,000                       
      write-down of commercial supply and inventory to net realizable value and settlement on non-cancellable purchase commitments
    		                                                           
      gain on lease modification
    		                           -3,169,000                                
      loss on extinguishment of debt
    		                          -30,977,000          -2,009,000                       
      income from continuing operations, before income taxes
    		                     44,500,000 35,812,000                                     
      income from continuing operations, net of income taxes
    		                     15,743,000 34,423,000                                     
      loss from discontinued operations, net of income taxes
    		                                                           
      income per share from continuing operations, net of income taxes—basic
    		                     0.27 0.22                                     
      income per share from continuing operations, net of income taxes—diluted
    		                     0.27 0.21                                     
      loss per share from discontinued operations, net of income taxes—basic and diluted
    		                                                           
      net income from continuing operations
    		                       25,204,000 3,345,000 47,858,000 20,648,000 12,283,000                                
      net loss from discontinued operations
    		                                                           
      product revenue
    		                             479,000 1,235,000 1,096,000 635,000 1,625,000 682,000 465,000 289,000                       
      cost of revenues, excluding amortization of acquired intangible assets
    		                         11,013,000 506,000 11,313,000 1,043,000 21,463,000 4,616,000 4,065,000 2,607,000 8,984,000 6,080,000                         
      write-down of commercial supply and inventory to net realizable value and (settlement) loss on non-cancellable purchase commitments
    		                          -3,530,000   61,750 -1,589,000                             
      amortization of acquired intangible assets
    		                              1,159,000 3,476,000 3,476,000 3,476,000 1,897,000                         
      gain on fair value remeasurement of contingent consideration
    		                                                           
      impairment of intangible assets
    		                              151,794,000                             
      weighted-average number of common shares—basic and diluted:
    		                          156,436 155,849                                
      write-down of commercial supply and inventory to net realizable value and loss on non-cancellable purchase commitments
    		                               1,836,000                            
      loss on fair value remeasurement of contingent consideration
    		                              -33,519,000 1,962,000 512,000 -39,229,000 -628,000 6,933,000 1,614,000 1,164,000 8,667,000                     
      weighted-average number of common shares used in net loss per share—basic and diluted:
    		                            154,956 152,634 153,227 152,163 151,013 148,993 149,502 148,778 147,786 144,928 145,180                     
      write-down of lesinurad commercial supply to net realizable value
    		                                 41,750 71,000                         
      cost of revenues, excluding amortization of acquired intangible asset
    		                                   3,502,000 531,000                       
      write-down of lesinurad commercial supply to net realizable value and loss on non-cancellable purchase commitments
    		                                   96,000                        
      amortization of acquired intangible asset
    		                                   421,000 420,000 -3,297,000 3,213,000 1,065,000                    
      cost of revenue, excluding amortization of acquired intangible asset
    		                                                           
      write-down of inventory to net realizable value and loss on non-cancellable purchase commitments
    		                                         9,488,000                  
      other (expense) income:
    		                                                           
      weighted-average number of common shares used in net loss per share — basic and diluted:
    		                                       144,642 143,593 142,473 142,098 141,278 139,234 138,315 129,745  113,441,391 108,072,643          
      cost of revenue
    		                                          8,150,000 12,000  10,518,000 1,924,000 2,021,000 3,418,000 1,231,000          
      collaboration expense
    		                                               6,182,000 11,162,000 24,730,000          
      basic net income per share
    		                                               -0.51   0.44         
      diluted net income per share
    		                                               -0.51   0.42         
      weighted-average number of common shares used in:
    		                                                           
      general and administrative
    		                                                  25,352,000 23,200,000 18,374,000 10,929,000 10,805,000 9,224,000 6,482,000 7,325,000 6,643,000 
      net income before income taxes
    		                                                  47,635,000         
      comprehensive income
    		                                                  47,651         
      weighted-average number of common shares used in net loss per share —basic and diluted
    		                                                   107,078,150 103,751,060       
      comprehensive loss
    		                                                   -40,815 -35,604,000       
      other comprehensive income:
    		                                                           
      unrealized gain on short-term investments
    		                                                           
      other comprehensive income
    		                                                           
      net loss from continuing operations before income tax expense
    		                                                           
      net income from discontinued operations
    		                                                        9,311,000   
      net income from discontinued operations attributable to noncontrolling interest
    		                                                           
      continuing operations
    		                                                     -0.21 -0.19 -0.19 -0.16   
      discontinued operations
    		                                                        0.08   
      weighted-average number of common shares used in net income per share attributable to ironwood pharmaceuticals, inc.—basic and diluted
    		                                                     100,174,100      
      net loss from discontinued operations attributable to noncontrolling interest
    		                                                           
      weighted-average number of common shares used in net loss per share attributable to ironwood pharmaceuticals, inc.—basic and diluted
    		                                                      99,674,969 99,075,187   63,957,966 
      remeasurement of forward purchase contracts
    		                                                           
      net loss from continuing operations before income tax benefit
    		                                                           
      weighted average number of common shares used in net loss per share attributable to ironwood pharmaceuticals, inc.—basic and diluted
    		                                                        97,925,657 97,642,330  
      revenue:
    		                                                           
      collaborative arrangements
    		                                                         9,188,000 8,838,000 
      services
    		                                                         1,771,000 214,000 
      total revenue
    		                                                         10,959,000 9,052,000 
      net loss attributable to noncontrolling interest
    		                                                         73,000 329,000 
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-09-30 2015-06-30 2015-03-31 2014-09-30 2014-06-30 2014-03-31 2013-09-30 2013-06-30 2013-03-31 2012-09-30 2012-06-30 2012-03-31 2011-09-30 2011-06-30 2011-03-31 2010-09-30 2010-06-30 2010-03-31 
                                                                 
        assets
      		                                                           
        current assets:
      		                                                           
        cash and cash equivalents
      		220,471,000 215,456,000 140,407,000 92,852,000 108,481,000 88,559,000 88,211,000 105,524,000 121,540,000 92,154,000 110,164,000 175,321,000 740,342,000 656,203,000 574,188,000 504,365,000 593,371,000 620,129,000 574,276,000 492,699,000 438,469,000 362,564,000 307,555,000 253,252,000 231,143,000 177,023,000 139,231,000 98,908,000 119,045,000 173,172,000 141,562,000 145,415,000 144,788,000 125,736,000 162,640,000 182,132,000 133,319,000 54,004,000 182,937,000 277,332,000 280,926,000 248,077,000 256,450,000 63,692,000 51,269,000 95,357,000 205,129,000 144,452,000 219,461,000 105,302,000 125,867,000 87,083,000 131,612,000 68,820,000 48,185,000 46,214,000 58,696,000 35,384,000 76,338,000 
        accounts receivable
      		105,842,000 46,745,000 120,370,000 86,172,000 39,768,000 81,886,000 76,202,000 58,108,000 72,015,000 129,122,000 124,546,000 118,990,000 115,749,000 115,458,000 116,545,000 102,357,000 105,515,000 114,042,000 101,773,000 102,252,000 87,152,000 122,351,000 113,250,000 105,379,000 17,703,000 11,279,000 2,017,000 22,604,000 3,291,000 20,991,000 10,193,000 6,748,000 4,988,000 3,190,000 4,280,000 3,975,000 1,152,000 933,000 1,174,000 1,272,000 908,000 2,570,000 1,057,000 862,000 380,000  13,000 125,000  12,000 169,000 22,000 109,000 74,000 110,000 207,000 372,000 196,000 192,000 
        prepaid expenses and other current assets
      		5,979,000 11,977,000 13,066,000 12,729,000 12,330,000 11,923,000 14,191,000 14,548,000 14,619,000 12,012,000 18,112,000 22,500,000 9,033,000 7,715,000 7,011,000 9,854,000 8,537,000 8,689,000 10,221,000 12,320,000 10,890,000 9,189,000 10,777,000 14,394,000 10,443,000 10,685,000 11,863,000 8,880,000 8,327,000 11,063,000 21,699,000 16,678,000 8,924,000 7,288,000 8,074,000 8,235,000 8,664,000 9,030,000 9,216,000 7,622,000 7,731,000 6,502,000 6,595,000 9,212,000 11,389,000 6,338,000 5,286,000 9,789,000 9,565,000 13,853,000 7,877,000 5,964,000 4,048,000       
        total current assets
      		332,292,000 274,178,000 273,843,000 191,753,000 160,579,000 182,368,000 178,604,000 178,180,000 208,174,000 233,288,000 253,610,000 317,599,000 866,374,000 780,626,000 698,994,000 617,826,000 710,101,000 745,225,000 695,374,000 620,268,000 538,246,000 495,839,000 433,317,000 374,275,000 333,943,000 306,852,000 257,638,000 220,985,000 201,832,000 266,435,000 248,548,000 279,542,000 275,727,000 311,596,000 314,053,000 341,487,000 357,853,000 380,181,000 382,804,000 386,142,000 495,701,000 505,779,000 526,959,000 263,876,000 304,081,000 325,760,000 371,305,000 275,826,000 335,780,000 275,634,000 202,347,000 166,083,000 206,265,000 178,766,000 208,382,000 229,052,000 263,282,000 282,159,000 306,398,000 
        property and equipment
      		3,166,000 3,408,000 3,666,000 3,929,000 4,256,000 4,495,000 4,795,000 5,068,000 5,288,000 5,585,000 5,630,000 5,876,000 6,015,000 6,288,000 6,660,000 6,964,000 7,229,000 7,575,000 7,912,000 8,105,000 8,501,000 8,929,000 9,324,000 11,190,000 12,164,000 12,429,000 11,381,000 6,665,000 19,017,000 17,270,000 16,161,000 16,335,000 16,844,000 17,274,000 17,175,000 17,854,000 18,633,000 20,512,000 18,842,000 17,939,000 19,446,000 23,183,000 25,017,000 27,477,000 30,415,000 33,560,000 35,524,000 37,231,000 35,013,000 36,100,000 36,470,000 34,859,000 35,140,000 32,875,000 33,484,000 35,074,000 33,286,000 29,117,000 23,540,000 
        operating lease right-of-use assets
      		8,896,000 9,340,000 9,775,000 10,201,000 10,619,000 11,028,000 11,430,000 11,823,000 12,208,000 12,586,000 12,956,000 13,319,000 13,674,000 14,023,000 14,365,000 14,700,000 15,028,000 15,350,000 15,666,000 15,975,000 16,279,000 16,576,000 16,868,000 17,156,000 17,447,000 17,743,000 19,793,000 25,569,000 84,833,000                               
        intangible assets
      		1,838,000 2,040,000 2,247,000 2,453,000 2,658,000 2,860,000 3,067,000 3,273,000 3,478,000 3,682,000 3,889,000 4,096,000                    152,953,000 156,429,000 159,905,000 163,381,000 165,278,000 165,699,000 166,119,000 182,722,000 185,935,000                    
        deferred tax assets
      		84,237,000 103,433,000 101,687,000 129,459,000 143,563,000 144,234,000 185,338,000 193,019,000 206,273,000 212,324,000 243,645,000 257,900,000 267,909,000 283,661,000 304,538,000 320,554,000 335,440,000 333,294,000 335,227,000 337,800,000                                        
        other assets
      		4,137,000 4,502,000 4,844,000 5,151,000 5,538,000 5,923,000 6,285,000 4,257,000 3,398,000 3,608,000 3,823,000 3,920,000 820,000 847,000 863,000 872,000 955,000 1,000,000 855,000 879,000 924,000 943,000 881,000 820,000 838,000 5,000 20,000 26,000 56,000 114,000 708,000 771,000 809,000 870,000 799,000 738,000 783,000 1,456,000 1,412,000 1,818,000 2,243,000 3,223,000 3,504,000 6,028,000 3,525,000 3,597,000 3,895,000 4,639,000 5,091,000 5,212,000 54,000 74,000 124,000 192,000 214,000 251,000 317,000 298,000 30,000 
        total assets
      		434,566,000 396,901,000 396,062,000 342,946,000 327,213,000 350,908,000 389,519,000 395,620,000 438,819,000 471,073,000 524,063,000 603,220,000 1,155,277,000 1,100,519,000 1,040,344,000 975,690,000 1,083,381,000 1,126,927,000 1,079,371,000 1,007,218,000 599,344,000 559,238,000 492,324,000 443,538,000 404,005,000 402,748,000 334,343,000 315,721,000 363,538,000 332,050,000 416,652,000 618,218,000 571,095,000 605,674,000 625,086,000 705,079,000 701,319,000 709,821,000 731,978,000 700,208,000 603,325,000 613,426,000 653,941,000 305,528,000 346,168,000 371,064,000 418,871,000 325,843,000 384,031,000 325,093,000 246,518,000 208,663,000 249,176,000 219,480,000 249,727,000 272,024,000 304,532,000 322,084,000 338,130,000 
        liabilities and stockholders' deficit
      		                                                           
        current liabilities:
      		                                                           
        accounts payable
      		3,237,000 2,898,000 1,613,000 1,389,000 5,827,000 2,127,000 3,236,000 3,227,000 6,222,000 7,830,000 4,698,000 3,505,000 118,000 483,000 795,000 317,000 532,000 935,000 414,000 466,000 842,000 661,000 1,972,000 2,104,000 2,781,000 3,978,000 4,505,000 7,872,000 11,203,000 18,123,000    15,958,000    17,702,000       6,103,000 3,393,000 4,844,000 2,436,000 6,569,000 3,303,000 2,652,000 6,921,000 1,996,000 2,390,000 6,507,000 2,918,000 5,857,000 5,202,000 5,116,000 
        accrued research and development costs
      		2,044,000 3,149,000 3,528,000 4,551,000 5,627,000 6,681,000 9,408,000 6,720,000 11,880,000 21,331,000 10,735,000 20,122,000 2,874,000 5,258,000 5,673,000 6,338,000 5,442,000 15,896,000 1,675,000 1,638,000 1,254,000 1,898,000 2,657,000 2,400,000 2,286,000 2,956,000 4,956,000 6,270,000 9,734,000 8,219,000 5,088,000 5,378,000 4,673,000 7,313,000 7,872,000 7,454,000 5,106,000 6,937,000 8,042,000 6,653,000 6,625,000 2,635,000 5,530,000 9,270,000 2,056,000 2,235,000 1,763,000 3,711,000 4,946,000 6,184,000 6,154,000 6,907,000 7,958,000 7,629,000 5,429,000 8,052,000 5,328,000 8,573,000 8,426,000 
        accrued expenses and other current liabilities
      		27,903,000 33,239,000 34,620,000 24,033,000 33,439,000 26,849,000 33,566,000 32,406,000 31,398,000 44,254,000 62,714,000 79,585,000 17,771,000 16,700,000 17,598,000 13,425,000 16,852,000 23,566,000 20,127,000 16,253,000 18,363,000 26,486,000 23,885,000 17,955,000 18,719,000 30,465,000 30,529,000 33,982,000 39,591,000 45,252,000 44,958,000 37,829,000 30,145,000 38,237,000 33,798,000 30,817,000 31,818,000 38,301,000 29,055,000 20,598,000 19,065,000 24,578,000                  
        current portion of operating lease liabilities
      		3,268,000 3,252,000 3,236,000 3,220,000 3,204,000 3,189,000 3,173,000 3,157,000 3,142,000 3,126,000 3,111,000 3,095,000 3,080,000 3,065,000 3,050,000 3,066,000 3,097,000 3,127,000 3,157,000 3,161,000 3,144,000 3,128,000 3,112,000 2,610,000 1,876,000 1,146,000 9,934,000 11,904,000 12,080,000                               
        current portion of convertible senior notes
      		199,855,000 199,680,000 199,506,000 199,332,000     199,800,000 199,560,000 199,321,000 199,083,000     120,581,000 116,858,000 114,832,000 112,852,000                                        
        total current liabilities
      		236,307,000 242,218,000 242,503,000 232,525,000 48,097,000 38,846,000 49,383,000 45,510,000 252,442,000 276,101,000 280,579,000 305,390,000 23,843,000 25,525,000 27,117,000 23,298,000 147,403,000 161,698,000 145,694,000 134,370,000 23,603,000 32,173,000 32,901,000 26,695,000 27,595,000 40,929,000 52,795,000 110,861,000 118,569,000 119,524,000 112,582,000 94,984,000 62,336,000 66,027,000 64,489,000 79,973,000 78,893,000 91,131,000 95,305,000 90,999,000 78,113,000 67,780,000 62,099,000 59,813,000 54,057,000 41,626,000 38,500,000 39,701,000 43,966,000 62,682,000 35,577,000 49,121,000 52,283,000 70,848,000 70,844,000 60,532,000 55,849,000 57,201,000 54,984,000 
        operating lease obligations, net of current portion
      		9,233,000 9,870,000 10,498,000 11,117,000 11,717,000 12,304,000 12,882,000 13,452,000 14,004,000 14,543,000 15,074,000 15,598,000 16,105,000 16,599,000 17,087,000 17,567,000 18,031,000 18,484,000 18,930,000 19,394,000 19,862,000 20,318,000 20,767,000 21,211,000 21,646,000 22,082,000                                  
        revolving credit facility
      		385,000,000 385,000,000 385,000,000 385,000,000 385,000,000 385,000,000 400,000,000 425,000,000 275,000,000 300,000,000 325,000,000 400,000,000                                                
        other liabilities
      		21,170,000 21,648,000 22,218,000 22,466,000 17,292,000 17,105,000 39,771,000 34,738,000 29,414,000 28,415,000 30,948,000 31,035,000 11,824,000 9,766,000 9,227,000 6,491,000 5,111,000 3,501,000 1,594,000 1,482,000 1,630,000 1,763,000 518,000 602,000 705,000 734,000 492,000 2,626,000 2,723,000 2,530,000 2,530,000 5,060,000 5,060,000 5,060,000 8,190,000 8,190,000 8,190,000 8,190,000 10,120,000 10,120,000 10,120,000 10,645,000 3,845,000     1,653,000 1,653,000 909,000     703,000     
        commitments and contingencies
      		                                                           
        stockholders’ deficit:
      		                                                           
        preferred stock, 0.001 par value...
      		                                                           
        class a common stock, 0.001 par value...
      		165,000 163,000 163,000 162,000 162,000 160,000 160,000 160,000 159,000 156,000 156,000 156,000 155,000 154,000 153,000 153,000 155,000 162,000 163,000 163,000 162,000 161,000 160,000 160,000 159,000 158,000 157,000 156,000 156,000 154,000 140,000 139,000 138,000 137,000 135,000 135,000 134,000 133,000 131,000 130,000 128,000 127,000 126,000 126,000 124,000 120,000 119,000 97,000 96,000 82,000 77,000 76,000 75,000 59,000 51,000 49,000 44,000 19,000 19,000 
        additional paid-in capital
      		1,416,431,000 1,412,780,000 1,408,836,000 1,405,224,000 1,400,612,000 1,395,317,000 1,390,549,000 1,382,220,000 1,373,022,000 1,355,195,000 1,374,908,000 1,366,989,000 1,357,359,000 1,348,600,000 1,336,153,000 1,328,290,000 1,350,268,000 1,543,357,000 1,558,760,000 1,546,420,000 1,536,160,000 1,528,535,000 1,515,004,000 1,506,671,000 1,497,171,000 1,478,823,000 1,466,886,000 1,421,215,000 1,413,077,000 1,394,603,000 1,378,195,000 1,357,224,000 1,333,791,000 1,318,536,000 1,303,123,000 1,293,292,000 1,273,853,000 1,258,398,000 1,237,569,000 1,226,311,000 1,214,174,000 1,196,345,000 1,188,807,000 1,068,685,000 1,037,784,000 1,029,501,000 1,016,271,000 809,911,000 803,363,000 657,320,000 643,154,000 637,478,000 632,029,000 538,241,000 534,749,000 530,374,000 523,809,000 518,217,000 516,403,000 
        accumulated deficit
      		-1,632,945,000 -1,673,718,000 -1,671,442,000 -1,711,522,000 -1,735,121,000 -1,697,735,000 -1,699,991,000 -1,703,637,000 -1,702,777,000 -1,698,615,000 -1,697,528,000 -1,712,849,000 -650,662,000 -696,376,000 -745,243,000 -795,560,000 -832,640,000 -937,608,000 -978,982,000 -1,034,827,000 -1,426,130,000 -1,466,056,000 -1,509,260,000 -1,543,683,000 -1,568,887,000 -1,572,232,000 -1,620,090,000 -1,640,738,000 -1,650,412,000 -1,591,128,000 -1,575,635,000 -1,401,284,000 -1,351,904,000 -1,308,760,000 -1,320,845,000 -1,288,548,000 -1,244,324,000 -1,191,823,000 -1,178,318,000                     
        accumulated other comprehensive loss
      		-795,000     923,000 -2,052,000 -470,000 -922,000 -3,031,000                      -44,000 -91,000 -79,000  -24,000 -41,000                       
        total stockholders’ deficit
      		-217,144,000 -261,835,000 -264,157,000 -308,162,000 -334,053,000 -301,335,000 -311,334,000 -321,727,000 -330,518,000               -36,852,000 -71,557,000 -93,251,000 -153,047,000 -219,367,000 -237,179,000                               
        total liabilities and stockholders’ deficit
      		434,566,000 396,901,000 396,062,000 342,946,000 327,213,000 350,908,000 389,519,000 395,620,000 438,819,000               443,538,000 404,005,000 402,748,000 334,343,000 315,721,000 363,538,000                               
        convertible senior notes, net of current portion
      		    199,160,000 198,988,000 198,817,000 198,647,000 198,477,000 198,309,000 198,141,000 197,974,000 396,653,000 396,251,000 395,850,000 395,451,000 395,053,000 337,333,000 333,212,000 329,155,000                                        
        accumulated other comprehensive income
      		 -1,060,000 -1,714,000 -2,026,000 294,000      -752,000                            61,000 39,000 29,000 48,000 22,000 3,000 25,000 3,000  19,000  12,000 7,000  3,000 6,000 53,000 52,000 48,000 44,000  
        liabilities and stockholders' equity
      		                                                           
        stockholders’ equity
      		                                                           
        restricted cash
      		          788,000 788,000 1,250,000 1,250,000 1,250,000 1,250,000 1,250,000 1,250,000 1,250,000 1,735,000 1,735,000 1,735,000 1,735,000 1,250,000 1,250,000 1,250,000 7,676,000 7,676,000 1,250,000 1,250,000 7,676,000 8,306,000 7,056,000 7,056,000 7,057,000 7,057,000 1,190,000 8,247,000 8,247,000 8,247,000  8,747,000 8,147,000 8,147,000 8,147,000 8,147,000 8,147,000 8,147,000 8,147,000 8,147,000 7,647,000 7,647,000 7,647,000    2,833,000 10,510,000 8,162,000 
        restricted cash, net of current portion
      		          510,000 510,000 485,000 485,000 485,000 485,000 485,000 485,000 485,000 485,000 485,000 485,000 485,000 971,000 971,000 971,000 971,000 971,000 6,426,000 6,426,000       7,057,000    8,247,000                   
        accounts receivable, net of current portion
      		             14,589,000 14,439,000 14,289,000 14,143,000 23,998,000 23,852,000 23,706,000 23,563,000 23,401,000 23,197,000 22,995,000 22,795,000 32,597,000 32,398,000                                 
        note hedge warrants
      		             19,000 1,000 152,000 899,000 1,316,000 5,489,000 11,061,000 7,979,000 12,088,000 7,695,000 12,958,000 12,207,000 24,260,000 8,768,000 50,191,000 39,388,000 33,763,000 122,778,000 143,019,000 96,129,000 92,188,000 103,743,000 149,458,000 133,424,000 113,237,000 120,121,000 86,838,000 68,193,000 62,976,000 69,456,000                 
        total stockholders’ equity
      		         -346,295,000 -325,679,000 -346,777,000 706,852,000 652,378,000 591,063,000 532,883,000 517,783,000 605,911,000 579,941,000 511,756,000 110,192,000 62,640,000 5,904,000           9,848,000  4,870,000 29,637,000 66,716,000 59,458,000 81,381,000 90,935,000 100,458,000 140,283,000 68,162,000 108,150,000 141,831,000 188,943,000 84,209,000 139,416,000 58,523,000 182,108,000 128,781,000 164,146,000 112,930,000 130,117,000 144,585,000 168,067,000 173,550,000 188,802,000 
        total liabilities and stockholders’ equity
      		         471,073,000 524,063,000 603,220,000 1,155,277,000 1,100,519,000 1,040,344,000 975,690,000 1,083,381,000 1,126,927,000 1,079,371,000 1,007,218,000 599,344,000 559,238,000 492,324,000           605,674,000  705,079,000 701,319,000 709,821,000 731,978,000 700,208,000 603,325,000 613,426,000 653,941,000 305,528,000 346,168,000 371,064,000 418,871,000 325,843,000 384,031,000 325,093,000 246,518,000 208,663,000 249,176,000 219,480,000 249,727,000 272,024,000 304,532,000 322,084,000 338,130,000 
        ironwood pharmaceuticals, inc. stockholders’ equity:
      		                                                           
        total ironwood pharmaceuticals, inc. stockholders’ equity
      		          -323,216,000 -345,704,000                                             168,067,000 170,740,000 185,919,000 
        noncontrolling interests
      		          -2,463,000 -1,073,000                                                
        stockholders’ equity:
      		                                                           
        convertible note hedges
      		                1,428,000 1,115,000 7,854,000 11,262,000 11,346,000 13,065,000 8,252,000 16,131,000 15,847,000 31,366,000 11,357,000 60,720,000 50,589,000 41,020,000 142,774,000 159,526,000 113,445,000 108,188,000 121,836,000 171,880,000 150,509,000 132,521,000 137,302,000 99,478,000 77,688,000 72,494,000 90,314,000                 
        convertible senior notes
      		                    436,078,000 430,256,000 424,539,000 418,924,000 413,409,000 407,994,000 402,675,000 274,395,000 269,947,000 265,601,000 261,355,000 257,206,000 253,153,000 249,193,000 245,324,000 241,544,000 237,851,000 234,243,000 230,717,000 227,273,000 223,908,000 217,408,000 214,292,000                 
        related party accounts receivable
      		                        73,404,000 105,967,000 94,553,000 81,182,000 69,326,000 59,959,000 55,182,000 73,771,000 65,663,000 78,967,000 75,803,000 56,382,000 49,995,000 63,921,000 52,541,000 51,875,000 52,110,000 34,401,000 25,992,000 32,987,000 14,306,000 4,455,000 10,324,000 2,961,000 5,298,000 36,000 13,000 2,444,000  667,000 2,517,000 3,977,000 4,677,000 6,156,000 4,531,000 
        inventory
      		                         648,000 2,298,000 1,735,000 593,000  76,000 1,099,000 1,705,000 735,000 479,000  1,513,000 1,081,000      4,950,000 13,045,000 12,989,000 23,413,000 20,561,000 20,379,000 19,704,000 965,000         
        related party accounts payable
      		                      400,000 751,000 1,058,000 1,509,000 1,593,000 2,036,000          1,000       6,000 5,000 18,000 5,789,000 7,268,000 26,441,000 2,141,000 3,705,000 1,175,000       
        deferred revenue
      		                      875,000 875,000 875,000 875,000 1,278,000    13,521,000     225,000 741,000                       
        current assets of discontinued operations
      		                                                           
        goodwill
      		                         785,000 785,000 785,000 785,000 785,000 785,000 785,000 785,000 785,000 785,000 785,000 785,000 785,000 649,000 649,000                    
        non-current assets of discontinued operations
      		                                                           
        capital lease obligations
      		                             73,000 171,000                             
        current portion of deferred rent
      		                             252,000 247,000 242,000 237,000 195,000 195,000 205,000 588,000 7,719,000 7,821,000 7,923,000 7,684,000 5,026,000 5,009,000 5,006,000 3,466,000 2,817,000 2,803,000 2,776,000 2,762,000 2,749,000 4,531,000 4,517,000 4,350,000 3,707,000 3,282,000 2,877,000 2,374,000 1,150,000 196,000 
        current portion of 2026 notes
      		                           48,797,000 45,961,000 47,554,000 39,191,000 24,861,000 11,958,000                           
        current portion of contingent consideration
      		                             51,000 74,000 423,000 355,000 247,000 699,000 14,985,000 14,561,000 14,244,000 14,578,000 597,000                    
        current liabilities of discontinued operations
      		                                                           
        capital lease obligations, net of current portion
      		                             158,000       21,000 82,000 141,000 198,000 253,000 1,068,000 1,959,000 2,268,000 2,868,000 3,158,000 2,842,000 3,427,000 198,000 254,000 361,000 364,000 435,000 481,000 540,000 598,000 429,000 427,000 74,000 
        deferred rent, net of current portion
      		                             6,308,000 6,113,000 6,058,000 5,860,000 5,449,000 4,484,000 3,515,000 2,554,000 557,000 2,490,000 4,409,000 7,131,000 7,714,000 8,821,000 9,935,000 8,091,000 7,431,000 8,127,000 9,519,000 10,218,000 10,907,000 9,690,000 10,832,000 11,964,000 13,308,000 14,379,000 13,939,000 15,772,000 16,330,000 10,703,000 
        2026 notes, net of current portion
      		                           78,330,000 90,140,000 100,537,000 108,589,000 122,614,000 135,220,000                           
        operating lease liabilities, net of current portion
      		                          22,660,000 18,685,000 79,950,000                               
        available-for-sale securities
      		                              19,836,000 35,831,000 49,659,000 95,680,000 62,777,000 90,763,000 162,020,000 251,212,000 136,936,000 48,041,000 153,526,000 214,229,000 236,865,000 152,173,000 213,692,000 206,621,000 127,140,000 97,938,000 81,077,000 136,727,000 67,456,000 70,570,000 70,496,000 106,309,000 152,912,000 174,355,000 192,135,000 236,221,000 222,230,000 
        liabilities and stockholders' (deficit) equity
      		                                                           
        contingent consideration, net of current portion
      		                               33,228,000 31,389,000 31,011,000 69,830,000 71,213,000 64,712,000 63,416,000 81,682,000 87,052,000                    
        stockholders’ (deficit) equity:
      		                                                           
        class b common stock, 0.001 par value...
      		                              14,000 14,000 14,000 14,000 14,000 15,000 15,000 15,000 15,000 15,000 16,000 16,000 16,000 16,000 16,000 18,000 19,000 24,000 25,000 27,000 31,000 32,000 32,000 42,000 49,000 51,000 55,000 79,000 79,000 
        total stockholders’ (deficit) equity
      		                             -196,371,000 -197,295,000 -43,951,000 -18,052,000  -17,579,000                         
        total liabilities and stockholders’ (deficit) equity
      		                             332,050,000 416,652,000 618,218,000 571,095,000  625,086,000                         
        accounts payable and related party accounts payable
      		                              9,332,000 23,786,000 11,609,000  17,514,000 21,190,000 20,578,000  19,752,000 8,999,000 4,741,000 5,904,000 6,650,000 5,227,000                
        revenues:
      		                                                           
        collaborative arrangements revenue
      		                              54,194,000 71,207,000 63,086,000  86,143,000                         
        product revenue
      		                              1,235,000 1,096,000 635,000  682,000                         
        sale of active pharmaceutical ingredient
      		                              10,257,000 8,803,000 5,434,000                           
        total revenues
      		                              65,686,000 81,106,000 69,155,000  86,825,000                         
        cost and expenses:
      		                                                           
        cost of revenues, excluding amortization of acquired intangible assets
      		                              4,616,000 4,065,000 2,607,000  6,080,000                         
        write-down of commercial supply and inventory to net realizable value and (settlement) loss on non-cancellable purchase commitments
      		                              -1,589,000                             
        research and development
      		                              46,794,000 38,932,000 36,505,000  37,065,000                         
        selling, general and administrative
      		                              55,248,000 68,363,000 61,923,000  61,774,000                         
        amortization of acquired intangible assets
      		                              1,159,000 3,476,000 3,476,000  1,897,000                         
        (gain) loss on fair value remeasurement of contingent consideration
      		                              -33,519,000    -628,000                         
        restructuring expenses
      		                              10,282,000 2,392,000                            
        impairment of intangible assets
      		                              151,794,000                             
        total cost and expenses
      		                              234,785,000 121,026,000 105,023,000  106,259,000                         
        income from operations
      		                              -169,099,000 -39,920,000 -35,868,000  -19,434,000                         
        other income:
      		                                                           
        interest expense
      		                              -9,482,000 -9,383,000 -9,273,000  -9,135,000                         
        interest and investment income
      		                              741,000 732,000 681,000  601,000                         
        gain on derivatives
      		                              3,489,000 -809,000 1,316,000  -4,329,000                         
        loss on extinguishment of debt
      		                                                           
        other income
      		                              -5,252,000 -9,460,000 -7,276,000  -12,863,000                         
        net income
      		                              -174,351,000 -49,380,000 -43,144,000  -32,297,000                         
        net income per share
      		                              -1,140 -320 -290  -220                         
        weighted-average number of common shares used in net income per share—basic and diluted:
      		                              153,227,000 152,163,000 151,013,000  149,502,000                         
        current portion of capital lease obligations
      		                               2,465,000 3,359,000 4,077,000 4,411,000 5,097,000 5,501,000 6,227,000 3,525,000 2,451,000 2,447,000 2,325,000 1,203,000 1,177,000 1,128,000 1,104,000 1,156,000 1,115,000 223,000 242,000 280,000 277,000 271,000 228,000 229,000 241,000 227,000 246,000 147,000 
        write-down of commercial supply and inventory to net realizable value and loss on non-cancellable purchase commitments
      		                               1,836,000                            
        loss on fair value remeasurement of contingent consideration
      		                               1,962,000 512,000                           
        pharma notes payable
      		                                                           
        2026 notes
      		                                 146,898,000 146,605,000 146,316,000 146,037,000                       
        write-down of lesinurad commercial supply to net realizable value
      		                                  71,000                         
        current portion of deferred revenue
      		                                      4,127,000 8,519,000 9,309,000 7,191,000 7,191,000 7,191,000 5,074,000 6,447,000 6,128,000 5,074,000 5,074,000 3,299,000 3,130,000 13,578,000 24,935,000 47,647,000 48,555,000 40,050,000 35,490,000 35,490,000 35,607,000 
        current portion of pharma notes payable
      		                                      8,405,000 35,259,000 28,242,000 20,121,000 17,571,000                 
        deferred revenue, net of current portion
      		                                         3,596,000 5,393,000 7,191,000 7,610,000 8,879,000 10,147,000 12,684,000 13,952,000 17,217,000 18,782,000 19,565,000 20,348,000 21,913,000 33,144,000 52,370,000 64,415,000 73,288,000 82,038,000 
        pharma notes payable, net of current portion
      		                                     132,249,000 131,944,000 111,938,000 124,672,000 141,781,000 147,793,000                 
        liabilities and stockholders’ equity
      		                                                           
        restricted cash, current portion
      		                                        500,000                   
        accrued expenses
      		                                          18,945,000 18,735,000 26,877,000 19,048,000 17,407,000 18,800,000 17,124,000 20,464,000 16,689,000 13,216,000 11,598,000 9,247,000 6,648,000 6,394,000 6,573,000 5,523,000 4,326,000 
        current portion of notes payable
      		                                           13,207,000 9,347,000 6,577,000 4,381,000             
        notes payable, net of current portion
      		                                           158,159,000 165,392,000 168,139,000 170,312,000             
        notes payable
      		                                               174,650,000 174,628,000 174,601,000          
        prepaid expenses and other assets
      		                                                     2,896,000 4,658,000 4,299,000 4,569,000 4,202,000 3,107,000 
        other current liabilities
      		                                                      194,000     
        long-term restricted cash
      		                                                        7,647,000   
        long-term assets of discontinued operations
      		                                                           
        current portion of long-term debt
      		                                                         1,017,000 1,166,000 
        long-term debt
      		                                                         1,288,000 1,529,000 
        long-term liabilities of discontinued operations
      		                                                           
        convertible preferred stock, 0.001 par value...
      		                                                           
        noncontrolling interest
      		                                                         2,810,000 2,883,000 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-09-30 2015-06-30 2015-03-31 2014-09-30 2014-06-30 2014-03-31 2013-09-30 2013-06-30 2013-03-31 2012-09-30 2012-06-30 2012-03-31 2011-09-30 2011-06-30 2011-03-31 2010-09-30 2010-06-30 2010-03-31 
                                                                  
          cash flows from operating activities:
        		                                                          
          net income
        		40,773,000 -2,276,000       -4,162,000 -1,745,000 13,950,000 -1,089,478,000 45,714,000 48,867,000 50,317,000 37,080,000 38,801,000 41,374,000 55,845,000 391,303,000 39,926,000 43,204,000 34,423,000 25,204,000 3,345,000                                  
          adjustments to reconcile net income to net cash from operating activities:
        		                                                          
          depreciation and amortization
        		443,000 460,000 475,000 467,000 479,000 485,000 507,000 506,000 513,000 512,000 507,000 270,000 286,000 340,000 363,000 360,000 355,000 359,000 358,000 396,000 410,000 421,000 1,821,000 640,000 682,000 867,000 3,174,000 297,000 1,242,000 1,265,000 1,386,000 1,671,000 1,790,000 1,764,000 1,928,000 2,910,000 2,761,000 2,198,000 2,487,000 2,833,000 2,788,000 3,152,000 2,891,000 3,168,000 3,085,000 3,126,000 3,070,000 2,789,000 2,788,000 3,032,000 2,810,000 2,680,000 2,286,000 2,904,000 2,133,000 1,440,000 1,502,000 1,303,000 
          share-based compensation expense
        		3,653,000 3,823,000 3,612,000 4,524,000 5,291,000 4,566,000 8,329,000 8,570,000 8,385,000 8,704,000 7,906,000 8,264,000 7,131,000 7,291,000 7,067,000 6,601,000 6,089,000 6,090,000 6,206,000 4,589,000 5,396,000 10,008,000 7,712,000 7,091,000 6,364,000 5,486,000 5,521,000 5,283,000 14,988,000 11,215,000 12,968,000 10,751,000 9,043,000 8,697,000 9,140,000 7,279,000 7,383,000 6,933,000 8,097,000 6,806,000 6,640,000 6,903,000 5,426,000 5,536,000 6,012,000 6,074,000 5,199,000 4,817,000 5,275,000 5,135,000 4,056,000 3,721,000 2,862,000 2,951,000 2,698,000 1,838,000 1,690,000 1,608,000 
          non-cash interest expense
        		419,000 418,000 418,000 416,000 416,000 415,000 350,000 550,000 589,000 587,000 586,000 485,000 402,000 400,000 400,000 516,000 537,000 6,148,000 6,037,000 5,928,000 5,822,000 5,718,000 5,615,000 5,514,000 5,416,000 4,058,000 6,232,000 4,691,000 4,609,000 4,557,000 4,453,000 4,352,000 4,239,000 4,069,000 3,972,000 3,877,000 3,831,000 3,760,000 3,649,000 3,572,000 3,429,000 800,000 370,000 413,000 402,000 386,000 387,000 484,000 453,000          
          non-cash lease expense
        		444,000 435,000 426,000 418,000 409,000                                                      
          deferred income taxes
        		19,196,000 -1,746,000 27,772,000 14,105,000 670,000 41,104,000 7,681,000 13,255,000 6,050,000 31,321,000 14,256,000 10,008,000 17,052,000 20,129,000 16,016,000 14,886,000 14,708,000 1,933,000 2,573,000                                        
          changes in assets and liabilities:
        		                                                          
          accounts receivable
        		-59,097,000 73,623,000 -34,193,000 -46,400,000 42,118,000 -5,684,000 -18,095,000 13,908,000 57,107,000 -4,577,000 -5,556,000 -3,241,000 14,298,000  -14,338,000 3,012,000 18,382,000                                   543,000 1,886,000     511,000 
          prepaid expenses and other current assets
        		5,997,000 1,086,000 -248,000 -64,000 -407,000 2,268,000 357,000 71,000 -2,607,000 6,101,000 4,387,000 -2,599,000 -3,669,000 1,646,000 2,842,000 -1,317,000 53,000 1,633,000 2,069,000 -1,420,000 -1,681,000 1,585,000 3,568,000 -3,939,000 301,000 -625,000 -3,068,000 166,000 2,481,000 9,743,000 -3,791,000 -7,726,000 -1,647,000 317,000 331,000 372,000 -146,000    46,000 2,193,000 483,000   938,000       1,762,000 -359,000 1,021,000    
          other assets
        		121,000 100,000 63,000 143,000 141,000 117,000 38,000 -1,039,000 30,000 35,000 -84,000 -297,000 27,000 16,000 9,000 83,000 45,000 -146,000 25,000 45,000 19,000 -62,000 -61,000 21,000 -51,000   -64,000 58,000 594,000 64,000 37,000 62,000 -61,000 45,000 201,000 -26,000 860,000 425,000 385,000       48,000 52,000 20,000 20,000 50,000 14,000 22,000 37,000 23,000    
          accounts payable and accrued expenses
        		-4,886,000 -318,000 10,693,000 -13,836,000 9,662,000 -5,752,000 69,000 -1,999,000 -12,526,000 -12,547,000 6,594,000 17,628,000 705,000  4,657,000 -3,648,000 -7,117,000                                8,897,000 -3,402,000      2,610,000   
          accrued research and development costs
        		-1,102,000 -274,000 -1,168,000 -1,610,000 -1,054,000 -2,727,000 2,688,000 -5,160,000 -9,451,000 5,595,000 -9,387,000 301,000 -2,384,000 -415,000 -665,000 896,000 -10,454,000 14,221,000 37,000 384,000 -644,000 -759,000 257,000 114,000 -670,000 -1,504,000 -1,314,000 820,000 1,515,000 3,131,000 -290,000 705,000 -2,640,000 418,000 2,348,000 -1,831,000 -1,105,000 1,389,000 28,000 2,380,000  -3,740,000 5,696,000      520,000   948,000       
          operating lease liabilities
        		-621,000 -612,000 -603,000 -584,000 -572,000 -562,000 -554,000 -537,000 -523,000 -516,000 -509,000 -491,000 -479,000 -473,000 -496,000 -495,000 -483,000 -476,000 -468,000 -451,000 -440,000 -433,000 58,000 299,000 294,000 -9,366,000 2,005,000 -1,856,000 -2,829,000                              
          other liabilities
        		-219,000 -141,000 249,000 3,669,000 187,000 -21,674,000 4,471,000 5,778,000 1,169,000 -3,006,000 -554,000 3,309,000 758,000 2,090,000 2,736,000 2,382,000 3,616,000 -1,101,000 111,000 -147,000 -133,000 1,247,000 -85,000 -104,000 -29,000                      0            
          net cash from operating activities
        		5,121,000 74,575,000 47,583,000 -15,068,000 19,954,000 15,214,000 9,885,000 33,465,000 44,985,000 35,834,000 32,459,000 34,963,000 80,171,000 79,182,000 69,092,000 61,365,000 64,124,000 64,568,000 75,065,000 48,568,000 73,694,000 51,513,000 53,632,000 20,088,000 43,603,000    -42,385,000 9,273,000 -26,578,000 -22,691,000 -30,886,000 -31,242,000 -31,261,000 -27,846,000 -18,686,000   161,000                   
          capital expenditures
        		 1,000 -2,000 -2,000 -31,000 0 -16,000 -58,000 -68,000 -211,000 -49,000 0 -13,000 27,000 -66,000 -88,000 -9,000 0 0 0  0 0 -376,000 -1,438,000    -3,235,000 -3,301,000 -2,120,000 -1,691,000 -1,509,000 -1,463,000 -709,000 -1,037,000 -1,198,000   0                   
          free cash flows
        		 74,576,000 47,581,000 -15,070,000 19,923,000 15,214,000 9,869,000 33,407,000 44,917,000 35,623,000 32,410,000 34,963,000 80,158,000 79,209,000 69,026,000 61,277,000 64,115,000 64,568,000 75,065,000 48,568,000  51,513,000 53,632,000 19,712,000 42,165,000    -45,620,000 5,972,000 -28,698,000 -24,382,000 -32,395,000 -32,705,000 -31,970,000 -28,883,000 -19,884,000   161,000                   
          cash flows from investing activities:
        		                                                          
          purchases of property and equipment
        		 1,000 -2,000 -2,000 -31,000 0 -16,000 -58,000 -68,000 -211,000 -49,000 0 -13,000 27,000 -66,000 -88,000 -9,000       -376,000 -1,438,000 -2,668,000 -3,077,000 1,791,000 -3,235,000 -3,301,000 -2,120,000 -1,691,000 -1,509,000 -1,463,000 -709,000 -1,037,000 -1,198,000                      
          net cash from investing activities
        		 1,000 -2,000 -2,000 -31,000 0 -16,000 -58,000 -68,000 -4,188,000 -22,625,000 -999,492,000 -13,000 27,000 -66,000 -88,000 -9,000 -128,000    -28,000 0 -376,000 -1,438,000 -2,661,000 -3,077,000 -2,429,000 -2,977,000 17,488,000 14,285,000 12,440,000 44,653,000 26,659,000 70,595,000 88,059,000 -115,424,000 -90,361,000 4,763,000 23,348,000   19,761,000         1,288,000       
          cash flows from financing activities:
        		                                                          
          proceeds from employee stock purchase plan
        		                                                          
          net cash from financing activities
        		 122,000 0 88,000 6,000 -14,887,000 -27,156,000 -49,372,000 -15,555,000 -50,904,000 -74,988,000 399,071,000 3,981,000 2,806,000 797,000 -150,283,000 -90,873,000 -18,587,000 6,164,000 5,662,000 2,211,000 3,524,000 670,000 2,397,000 11,955,000  8,633,000 -7,500,000 -8,765,000 4,849,000 7,810,000 12,128,000 5,285,000 -14,909,000 9,479,000 19,102,000 5,177,000      5,418,000 2,475,000 6,963,000 194,005,000 967,000 141,116,000 170,300,000 469,000 1,333,000 86,104,000 565,000 1,349,000 599,000 -581,000 -314,000 203,109,000 
          effect of exchange rate changes on cash and cash equivalents
        		-106,000 351,000 -26,000 -647,000 -7,000                                                      
          net increase in cash and cash equivalents
        		5,015,000 75,049,000 47,555,000 -15,629,000 19,922,000                             -19,492,000 48,813,000 79,315,000 -128,933,000 -94,395,000 -3,594,000 19,639,000     -109,772,000 129,639,000 -75,009,000     44,330,000 20,635,000 1,971,000 1,893,000    
          cash and cash equivalents, beginning of period
        		215,456,000 0 0 0 88,559,000                             0 0 54,004,000 0 0 0 261,287,000 0 0 74,297,000 0 0 75,490,000 0 0 136,700,000 0 0 87,282,000 0 0 44,321,000 -839,000 0 123,145,000 
          cash and cash equivalents, end of period
        		220,471,000 75,049,000 47,555,000 -15,629,000 108,481,000                             -19,492,000 48,813,000 133,319,000 -128,933,000 -94,395,000 -3,594,000 280,926,000 -8,373,000 192,758,000 63,692,000 -44,088,000 -109,772,000 205,129,000 -75,009,000 114,159,000 105,302,000 38,784,000 -44,529,000 131,612,000 20,635,000 1,971,000 46,214,000 23,312,000 -40,954,000 76,338,000 
          loss on disposal of property and equipment
        		 -3,000 7,000   0 5,000 37,000 33,000         0 76,000 0 17,000 2,000 45,000 407,000 16,000 37,000 0 -477,000 586,000 -276,000 -1,316,000   568,000            53,000      1,000    22,000 222,000 5,000 
          proceeds from exercise of stock options and employee stock purchase plan
        		 122,000 0 88,000 6,000 203,000 0 749,000 10,061,000 998,000 12,000   2,806,000 797,000 4,315,000 1,622,000 5,544,000 6,164,000 5,662,000 2,211,000 3,524,000 670,000 2,397,000 11,955,000 6,447,000 1,944,000 1,717,000 3,487,000 4,909,000 8,108,000 12,841,000 6,203,000 906,000 10,302,000 8,171,000 14,288,000 4,390,000 4,322,000 1,841,000 933,000 2,995,000 7,946,000 2,741,000 7,212,000 3,852,000 1,318,000 3,425,000 3,090,000 538,000         
          taxes paid related to net share settlement of share-based awards
        		     0 0 -121,000 -616,000                                                  
          repayment of 2024 convertible notes
        		     0                                                     
          proceeds from revolving credit facility
        		     0 0   0 0                                                
          costs associated with revolving credit facility
        		     -90,000    -591,000 0                                                
          repayments of revolving credit facility
        		     -15,000,000 -25,000,000 0 -25,000,000 -25,000,000                                                 
          supplemental cash flow disclosure:
        		                                                          
          cash paid for interest
        		                                                 -8,000 12,000 12,000 12,000 20,000 15,000 128,000 84,000 96,000 
          cash paid for income taxes
        		                                                          
          repayment on 2024 convertible notes
        		                                                          
          net loss
        		   23,599,000 -37,386,000  3,646,000                    20,648,000 12,283,000 -59,284,000 -15,493,000 -174,351,000 -49,380,000 -43,144,000 -32,297,000 -44,224,000 -52,501,000 -13,505,000 -33,204,000 -21,702,000 -13,297,000 -47,390,000 -48,020,000 -33,222,000 -41,988,000 -60,357,000 -49,626,000 -61,775,000 -65,149,000 -93,902,000 47,635,000 -40,803,000 -35,601,000 -20,633,000 -18,844,000 -18,401,000 -6,747,000 -17,209,000 -16,253,000 
          adjustments to reconcile net loss to net cash from operating activities:
        		                                                          
          change in fair value of note hedge warrants
        		         0 0 0 -19,000 18,000 -151,000 -747,000 -417,000 -4,173,000 -5,572,000 3,082,000 -4,109,000 4,393,000 -5,263,000 751,000 -12,053,000 15,492,000 -15,688,000 10,803,000 5,625,000 -89,015,000 -20,241,000 46,890,000 3,941,000 -45,715,000 16,034,000 20,187,000 -6,884,000 33,283,000                     
          acquired in-process research and development
        		         5,000,000 0                                                
          operating lease right-of-use assets
        		     402,000 393,000 385,000 378,000 370,000 363,000 355,000 349,000 342,000 335,000 328,000 322,000 316,000 309,000 304,000 297,000 292,000 288,000 291,000 296,000 2,050,000 5,776,000 2,849,000 3,466,000                              
          acquisition of vectivbio holding ag, net of cash acquired
        		         -3,977,000 -22,576,000                                                
          purchase of subsidiary shares from noncontrolling interests
        		                                                          
          repayment of 2022 convertible notes
        		                                                          
          repurchases of common stock
        		             0 0 -33,899,000 -92,495,000                                          
          effect of exchange rate changes on cash, cash equivalents and restricted cash
        		     21,000 -26,000 -51,000 24,000 -50,000                                                 
          net increase in cash, cash equivalents and restricted cash
        		       -16,016,000 29,386,000   -565,458,000 84,139,000 82,015,000 69,823,000 -89,006,000 -26,758,000 45,853,000 81,092,000 54,230,000 75,905,000 55,009,000 54,302,000 22,109,000 54,120,000 31,366,000 40,323,000 -19,166,000 -54,127,000 31,610,000 -4,483,000 1,877,000 19,052,000                          
          cash, cash equivalents and restricted cash, beginning of period
        		     0 0 0 92,154,000 0 0 0 657,938,000 0 0 0 621,864,000 0 0 0 364,784,000 0 0 0 179,244,000 0 0 0 180,848,000 0 0 0 132,792,000                          
          cash, cash equivalents and restricted cash, end of period
        		     348,000 -17,313,000 -16,016,000 121,540,000 -19,308,000 -65,157,000 -565,458,000 742,077,000 82,015,000 69,823,000 -89,006,000 595,106,000 45,853,000 81,092,000 54,230,000 440,689,000 55,009,000 54,302,000 22,109,000 233,364,000 31,366,000 40,323,000 -19,166,000 126,721,000 31,610,000 -4,483,000 1,877,000 151,844,000                          
          reconciliation of cash, cash equivalents, and restricted cash to the consolidated balance sheets
        		                                                          
          cash and cash equivalents
        		     348,000 -17,313,000 -16,016,000 121,540,000 -18,010,000 -65,157,000 -565,021,000 740,342,000 82,015,000 69,823,000 -89,006,000 593,371,000 45,853,000 81,577,000 54,230,000 438,469,000  54,303,000 22,109,000 231,143,000 37,792,000 40,323,000 -20,137,000 119,045,000 31,610,000 -3,853,000 627,000 144,788,000                          
          restricted cash
        		          0 -437,000 1,735,000 0 0 0 1,735,000 0 -485,000 0 2,220,000  -1,000 0 2,221,000 -6,426,000 0 971,000 7,676,000 0 -630,000 1,250,000 7,056,000 0   0 0               0 0 2,833,000   269,000 
          total cash, cash equivalents, and restricted cash
        		     348,000 -17,313,000 -16,016,000 121,540,000 -19,308,000 -65,157,000 -565,458,000 742,077,000 82,015,000 69,823,000 -89,006,000 595,106,000 45,853,000 81,092,000 54,230,000 440,689,000  54,302,000 22,109,000 233,364,000 31,366,000 40,323,000 -19,166,000 126,721,000 31,610,000 -4,483,000 1,877,000 151,844,000                          
          non-cash investing and financing activities
        		                                                          
          stock option exercise proceeds receivable in other current assets
        		                                                          
          net decrease in cash, cash equivalents and restricted cash
        		                                                          
          reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
        		                                                          
          change in fair value of convertible note hedges
        		             0 0 1,428,000 -313,000 6,739,000 3,408,000 84,000 1,719,000 -4,813,000 7,879,000 -284,000 15,519,000 -20,009,000 20,454,000 -10,131,000 -9,569,000 101,754,000 16,752,000 -46,081,000 -5,257,000 50,044,000 -21,371,000 -17,988,000 4,781,000   8,778,000 17,820,000                  
          stock repurchases payable in accrued expenses
        		                                                          
          payment on 2022 convertible notes
        		             0 0                                            
          proceeds from exercise of stock options
        		            3,981,000                                       945,000       
          accounts receivable and related party accounts receivable
        		                 -12,415,000 333,000 -15,243,000 35,037,000 -9,305,000 -8,073,000 -14,472,000 35,941,000 -22,181,000 -25,183,000 -29,862,000 8,333,000 -15,575,000 15,144,000 -9,868,000 11,506,000 -19,726,000 -9,210,000 13,707,000 -11,139,000 -568,000 -129,000 1,500,000         1,439,000          
          inventory
        		                     0 0    -451,000 -483,000 -152,000 -93,000 279,000 -224,000 -768,000 0 1,010,000 71,000      0 4,000 -48,000               
          accounts payable, related party accounts payable, and accrued expenses
        		                                                          
          deferred revenue
        		                         -403,000         -516,000 741,000 -4,127,000   320,000                   
          gain on lease modification
        		                         0 0                                
          settlement on non-cancellable purchase commitments
        		                                                          
          loss on extinguishment of debt
        		                         0        0 0 2,009,000                       
          accounts payable, related party accounts payable and accrued expenses
        		                 4,066,000 3,718,000 -2,486,000 -7,942,000 890,000 5,448,000 -2,093,000 -11,768,000 4,575,000 -12,070,000 -11,751,000 -13,454,000 10,823,000 -9,042,000 18,576,000 -12,300,000 -1,314,000 -107,000 -5,238,000 3,382,000                      
          net cash from continuing operating activities
        		                     51,513,000 53,632,000 20,088,000 43,603,000 27,580,000 34,767,000                                
          net cash from discontinued operating activities
        		                         0 0                                
          proceeds from sale of property and equipment
        		                         7,000 0 3,000 258,000 936,000 355,000 239,000 33,000 38,000 36,000 43,000 224,000    10,000 4,000 23,000         4,000       
          net cash (used in) continuing investing activities
        		                                                          
          net cash (used in) discontinued investing activities
        		                                                          
          proceeds from issuance of convertible senior notes
        		                         0               0                  
          purchase of capped calls
        		                         0                                 
          proceeds from partial termination of convertible note hedges and note hedge warrants
        		                                                          
          costs associated with issuance of convertible senior notes
        		                         0                                 
          payments for partial repurchase of 2022 convertible notes
        		                         0                                 
          payments on 8.375% notes due 2026
        		                                                          
          ​
        		                                                          
          recognition of asset retirement obligation
        		                                                          
          fixed asset purchases in accounts payable and accrued expenses
        		                                                          
          purchase of property and equipment
        		                                                          
          amortization of acquired intangible assets
        		                             0 1,159,000 3,476,000 3,476,000                          
          impairment of intangible assets
        		                             0                             
          write-down of commercial supply and inventory to net realizable value and (settlement) loss on non-cancellable purchase commitments
        		                         0                                 
          write-down of excess non-cancellable zurampic and duzallo sample purchase commitments
        		                             0 0                            
          accretion of discount/premium on investment securities
        		                             -8,000 -19,000 -20,000 -118,000 -80,000 6,000 105,000 106,000 104,000 117,000 340,000 424,000 137,000 161,000 358,000 330,000 136,000 197,000 500,000 387,000 261,000 270,000 309,000 509,000 615,000 727,000 408,000 389,000 98,000 
          non-cash change in fair value of contingent consideration
        		                             0 -33,519,000 1,962,000 512,000 -628,000 6,933,000 1,614,000 1,164,000                      
          deferred rent
        		                             200,000 60,000 203,000 453,000 959,000 578,000 -3,555,000 -2,035,000                   666,000 6,581,000 233,000 
          purchases of available-for-sale securities
        		                             0 -750,000 0 -2,491,000 -40,022,000 -45,929,000 -44,777,000 -147,887,000                      
          sales and maturities of available-for-sale securities
        		                             19,853,000 16,800,000 13,892,000 48,620,000 68,106,000 117,197,000 133,830,000 33,437,000 21,623,000 105,378,000 76,985,000 73,012,000 45,000,000 94,006,000 26,514,000 47,451,000 74,518,000 45,685,000 80,852,000 13,290,000 19,110,000 20,960,000 29,265,000 70,489,000 38,475,000 68,111,000 91,870,000   
          net cash from continuing investing activities
        		                     -28,000 0 -376,000 -1,438,000 -2,661,000 -3,077,000                                
          net cash from discontinued investing activities
        		                         0 0                                
          payments on capital lease obligations
        		                                                          
          payments on contingent purchase price consideration
        		                             -58,000 14,000 -30,000 -91,000 -15,002,000 0 -56,000                       
          net cash from continuing financing activities
        		                     3,524,000 670,000 2,397,000 11,955,000 6,447,000 8,633,000                                
          net cash from discontinued financing activities
        		                                                          
          write-down of commercial supply and inventory to net realizable value and settlement on non-cancellable purchase commitments
        		                                                          
          payments on 2026 notes
        		                         0                                 
          gain on facility subleases
        		                                                          
          principal payments on pharma notes
        		                                 0 0 -134,258,000 -8,405,000                      
          costs associated with issuance of 2026 notes
        		                                 0 -26,000 -209,000 -46,000                      
          proceeds from issuance of 2026 notes, net of discount to lender
        		                                 0 0 146,250,000                       
          net cash (used in) provided financing activities
        		                                                          
          purchases under capital leases
        		                                                 127,000 0 120,000 0 0 325,000 42,000   
          extinguishment of capital leases
        		                                                          
          net cashed used in operating activities
        		                          34,767,000                                
          proceeds from partial termination of convertible note hedges and warrants
        		                                                          
          write-down of commercial supply and inventory to net realizable value and loss on non-cancellable purchase commitments
        		                                                          
          principal payments on 2026 notes
        		                           -9,217,000 -12,252,000                              
          payment for acquisition of lesinurad license
        		                                    0                      
          contingent consideration
        		                                    -28,375,000 8,611,000                     
          payments on capital leases
        		                              -312,000 -683,000 -827,000 -813,000 -797,000 -796,000 -660,000                      
          gain on disposal of property and equipment
        		                                -34,000                          
          write-down of excess non-cancellable zurampic sample purchase commitments
        		                                                          
          write-down of excess non-cancelable zurampic sample purchase commitments
        		                                 0 0 1,353,000                       
          write-down of lesinurad commercial supply to net realizable value
        		                                                          
          loss on facility subleases
        		                                 0 0 -1,579,000 0 0 0 3,480,000                   
          non-cash investing activities
        		                                                          
          amortization of acquired intangible asset
        		                                  421,000 420,000 -3,297,000 3,213,000                     
          write-down of lesinurad commercial supply to net realizable value and loss on non-cancellable purchase commitments
        		                                                          
          write-down of inventory to net realizable value and loss on non-cancellable purchase commitments
        		                                                          
          proceeds from issuance of common stock
        		                                           0 0 190,428,000 0   0 0 85,228,000       
          proceeds from issuance of note hedge warrants
        		                                        0                  
          purchase of convertible note hedges
        		                                                          
          disposals under capital leases
        		                                                          
          net cash (used in) provided by financing activities
        		                                                          
          net cash provided by financing activities
        		                                        -3,975,000                  
          net increase (decrease) in cash and cash equivalents
        		                                                          
          write-down of inventory to net realizable value and loss on non-cancelable purchase commitments
        		                                                          
          adjustments to reconcile net loss to net cash used in operating activities:
        		                                                          
          principal payments on debt
        		                                                          
          write-down of inventory to net realizable value
        		                                           0               
          proceeds from issuance of notes payable
        		                                              0 0 175,000,000          
          costs associated with issuance of notes payable
        		                                                          
          supplemental cash flow disclosures:
        		                                                          
          payments on borrowings
        		                                                          
          income from discontinued operations
        		                                                          
          loss from continuing operations
        		                                                          
          net cash from operating activities from continuing operations
        		                                                          
          net cash from operating activities from discontinued operations
        		                                                          
          total net cash from operating activities
        		                                                          
          proceeds from sale of subsidiary
        		                                                          
          net cash from investing activities from continuing operations
        		                                                    45,485,000 18,830,000 25,207,000    
          net cash from investing activities from discontinued operations
        		                                                          
          total net cash from investing activities
        		                                                    45,485,000 18,830,000 25,207,000    
          proceeds from initial public offering
        		                                                       0 -1,000 203,168,000 
          proceeds from exercise of stock options, stock purchase plan and issuance of restricted stock
        		                                                    625,000      
          net cash from financing activities from continuing operations
        		                                                    565,000 1,349,000 599,000    
          net cash from financing activities from discontinued operations
        		                                                          
          debt and interest paid by purchases of subsidiary
        		                                                          
          loss from discontinued operations
        		                                                          
          proceeds from exercise of stock options and issuance of restricted stock
        		                                                      675,000 749,000 112,000 354,000 
          income (loss) from discontinued operations
        		                                                          
          remeasurement of forward purchase contracts
        		                                                          
          proceeds from the sale of property and equipment
        		                                                        0 1,000 
          proceeds from issuance of preferred stock, net of issuance costs
        		                                                          
          proceeds from borrowings
        		                                                          
          debt and interest paid by purchaser of subsidiary
        		                                                          
          fair value of forward purchase contract
        		                                                          
          settlement of forward purchase contract related to forest agreement
        		                                                          
          net decrease in cash and cash equivalents